Vera Therapeutics, Inc. (VERA) intrinsic value & 10-year financials
Vera Therapeutics, Inc. (VERA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $27.88
- Market cap
- $1.8B
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -80.3%
- Free cash flow (FY2025)
- -$241.7M
VERA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$299.6M | -$4.66 | -$241.7M | — | -73.0% |
| FY2024 | — | -$152.1M | -$2.75 | -$135.7M | — | -51.8% |
| FY2023 | — | -$96.0M | -$2.25 | -$92.2M | — | -120.5% |
| FY2022 | — | -$89.1M | -$3.35 | -$67.7M | — | -319.3% |
| FY2021 | — | -$32.6M | -$1.22 | -$23.7M | — | 46.4% |
| FY2020 | — | -$53.4M | — | -$34.9M | — | 36.5% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Vera Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Vera Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -27.6% ROIC.
Vera Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Vera Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.